Answers are grounded in this paper and cite their sources.
Observational study links immune-related adverse events to treatment response in early-stage triple-negative breast cancer, suggesting new predictive markers.
In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.
No takes yet. Share an insight, caveat, or question.
Güren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: